{
    "clinical_study": {
        "@rank": "168268", 
        "arm_group": [
            {
                "arm_group_label": "Standard of Care (SoC)", 
                "arm_group_type": "Other", 
                "description": "SoC include any active or inactive adjunctive treatment to hemostasis methods currently used based on each surgeons surgical practice except for the use of other fibrin sealants."
            }, 
            {
                "arm_group_label": "Bioseal Fibrin Sealant", 
                "arm_group_type": "Experimental", 
                "description": "A porcine-derived fibrin sealant consisting of thrombin and fibrinogen"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to observe the clinical utility and performance of Bioseal\n      when used as an adjunct to hemostasis versus Standard of Care (SoC) in elective meningioma\n      surgery."
        }, 
        "brief_title": "Phase IV Bioseal Study in Meningioma Surgery", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hemostasis", 
            "Meningioma Surgery"
        ], 
        "condition_browse": {
            "mesh_term": "Meningioma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects between 18 and 75 years of age\n\n          -  Undergoing elective meningioma surgery and having a tumor cavity\n\n          -  Presence of an appropriate Target Bleeding Site (TBS) as identified intra-operatively\n             by the surgeon  requiring an adjunct to achieve hemostasis\n\n          -  Able  and willing to comply with procedures required by protocol\n\n          -  Signed and dated written informed consent prior to any study related procedures.\n\n        Exclusion Criteria:\n\n          -  Subjects undergoing emergency surgery\n\n          -  Subjects with any intra-operative findings that may preclude conducting of the study\n             procedures\n\n          -  Intended use of Fibrin Sealants (including autologous Fibrin Sealants) other than\n             Bioseal on the TBS\n\n          -  Subjects with known intolerance to blood products or to one of the components of the\n             study product or unwilling to receive blood products\n\n          -  Subjects who have a history of traumatic head injury\n\n          -  Female subjects who are known breastfeeding or pregnant or intend to become pregnant\n             during the clinical study period\n\n          -  The subject, in the opinion of the investigator, would not be suitable for\n             participation in the study\n\n          -  Subjects who participated in another trial within 30 days prior to the planned start\n             of treatment."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "250", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02034799", 
            "org_study_id": "BIOS-13-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "Bioseal Fibrin Sealant", 
                "intervention_name": "Bioseal Fibrin Sealant", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Standard of Care (SoC)", 
                "intervention_name": "Standard of Care (SoC)", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Fibrin Tissue Adhesive"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 17, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Zhengzhou", 
                        "country": "China", 
                        "state": "Henan", 
                        "zip": "450052"
                    }, 
                    "name": "Clinical Investigation Site #6"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Changsha", 
                        "country": "China", 
                        "state": "Hunan", 
                        "zip": "410008"
                    }, 
                    "name": "Clinical Investigation Site #5"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China", 
                        "state": "Sichuan", 
                        "zip": "610041"
                    }, 
                    "name": "Clinical Investigation Site #3"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hangzhou", 
                        "country": "China", 
                        "state": "Zhejiang", 
                        "zip": "310009"
                    }, 
                    "name": "Clinical Investigation Site #4"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "zip": "100048"
                    }, 
                    "name": "Clinical Investigation Site #7"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "zip": "200040"
                    }, 
                    "name": "Clinical Investigation Site #2"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "zip": "300052"
                    }, 
                    "name": "Clinical Investigation Site #1"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Standard of Care as an Adjunct to Hemostasis in Elective Meningioma Surgery", 
        "overall_contact": {
            "last_name": "Jonathan Batiller, MBA", 
            "phone": "908-218-2492"
        }, 
        "overall_contact_backup": {
            "last_name": "Xiaowei Sun, MD, PhD", 
            "phone": "+86 10 5952 3103"
        }, 
        "overall_official": {
            "affiliation": "Ethicon, Inc.", 
            "last_name": "Richard Kocharian, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Hemostasis at the TBS at 6 minutes following treatment application.  Hemostasis is defined as no detectable bleeding at the TBS.", 
            "safety_issue": "No", 
            "time_frame": "Intra-operative"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02034799"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Hemostasis at the TBS at 3 minutes following  treatment application", 
                "safety_issue": "No", 
                "time_frame": "Intra-operative"
            }, 
            {
                "measure": "Incidence of neurosurgical complications, central nervous system events and surgical wound complications.", 
                "safety_issue": "Yes", 
                "time_frame": "Through 30-day follow-up"
            }, 
            {
                "measure": "Incidence of potential bleeding-related adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Through 30-day follow-up"
            }
        ], 
        "source": "Ethicon, Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Guangzhou Bioseal Biotechnology Co., Ltd.", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Ethicon, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}